Erymildbraedin A and B, two novel cytotoxic dimethylpyrano-isoflavones from the stem bark of Erythrina mildbraedii: evaluation of their activity toward endocrine cancer cells

J Enzyme Inhib Med Chem. 2010 Apr;25(2):228-33. doi: 10.3109/14756360903169972.

Abstract

Two new dimethylpyrano-isoflavones, named erymildbraedin A (4) and B (5), were isolated from the stem bark of the Cameroonian medicinal plant Erythrina mildbraedii, along with four known ones, the linear congeners, scandenone (1), erysenegalinsein M (2), 5,4'-dihydroxy-2'-methoxy-8-(3,3-dimethylallyl)-2'',2''-dimethylpyrano[5,6:6,7]isoflavone (3), and the angular isoflavone eryvarin B (6), and two other compounds, fraxidin and scoparone. Their structures were elucidated by the usual spectroscopic methods and isoflavone effects on the growth of human breast, prostate, and endometrial adenocarcinoma cells were determined. Isoflavones 1, 3, and 6 strongly inhibited the growth of all three cell lines, supporting the notion that a non-oxidized isoprenyl group at C-8 is requisite for cytotoxic activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / pathology
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / pathology
  • Cell Line, Tumor
  • Cell Proliferation / drug effects*
  • Drug Evaluation, Preclinical
  • Endometrial Neoplasms / drug therapy
  • Endometrial Neoplasms / pathology
  • Erythrina / chemistry*
  • Female
  • Humans
  • Isoflavones* / chemistry
  • Isoflavones* / isolation & purification
  • Isoflavones* / pharmacology
  • Male
  • Phytotherapy
  • Plant Bark / chemistry
  • Plant Extracts / chemistry
  • Plant Stems / chemistry
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / pathology
  • Structure-Activity Relationship

Substances

  • Isoflavones
  • Plant Extracts